MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML

Yin Xiong, Zejuan Li, Min Ji, Aik Choon Tan, Judson Bemis, Jove Victor Tse, Gang Huang, Jino Park, Chunyan Ji, Jianjun Chen, Lynne T. Bemis, Kevin D. Bunting, William Tse

Research output: Contribution to journalArticle

26 Scopus citations


MLLT11, an MLL fusion partner, is a poor prognostic biomarker for paediatric acute myeloid leukaemia (AML), adult normal cytogenetics AML, and adult myelodysplastic syndrome. MLLT11 is highly regulated during haematopoietic progenitor differentiation and development but its regulatory mechanisms have not been defined. In this study, we demonstrate by transfection experiments that MIR29B directly regulates MLLT11 expression in vitro. MIR29B expression level was also inversely related to MLLT11 expression in a cohort of 56 AML patients (P<0·05). AML patients with low MIR29B/elevated MLLT11 expression had poor overall survival (P=0·038). Therefore, MIR29B may be a potential prognostic biomarker for AML patients.

Original languageEnglish (US)
Pages (from-to)753-757
Number of pages5
JournalBritish journal of haematology
Issue number6
StatePublished - Jun 1 2011



  • AML prognostic marker
  • AML survival
  • MIR29
  • MLL fusion gene
  • MLLT11

Cite this